Since not all patients respond to BAT — as determined by decreased serum PSA or tumor volume, or by longer radiographic progression-free survival — and the degree and durability of response are unpredictable, identification of prognostic and predictive biomarkers is needed (10, 11). Here, KLK3 is linked to neoplasm.